Sjogren's Disease and Dry Eye
Sjogren's Dry Eye Treatment
Sjogren's-associated dry eye needs a different approach than standard evaporative dry eye. Here is the layered, evidence-based framework, from foundation lubricants to in-office procedures and coordinated systemic care.
Key takeaways
- Sjogren's dry eye is mainly aqueous-deficient, so it needs more aggressive, layered care than evaporative dry eye.
- Preservative-free lubrication is the daily baseline, and anti-inflammatory therapy is standard for moderate-to-severe disease.
- Punctal plugs are often the most impactful single step, best placed after inflammation is controlled.
- The surface should never be managed in isolation; care is coordinated with rheumatology.
Why treatment is different
Standard dry eye is mainly evaporative, where the meibomian glands do not make enough lipid to slow evaporation. Sjogren's dry eye is mainly aqueous-deficient, where the lacrimal gland is damaged by the immune system and cannot make enough of the watery tear layer. That difference drives a more aggressive, layered treatment plan, usually shared with a rheumatologist.
Layer 1. Lubrication and surface protection
Every patient, every day. The surface is already damaged and inflamed, so preservatives such as benzalkonium chloride (BAK) are harsh on compromised cells. Preservative-free drops are the baseline, and dosing is often much more frequent than for evaporative dry eye, sometimes hourly, which is expected and appropriate.
- Preservative-free artificial tears, used frequently through the day
- Nighttime gels or ointments for overnight exposure, especially with incomplete lid closure
- Autologous serum eye drops, blood-derived drops rich in growth factors, for moderate-to-severe disease that has not responded to standard lubricants
Layer 2. Anti-inflammatory therapy
The standard of care for moderate-to-severe disease, not an upgrade. The immune-driven lacrimal gland inflammation must be actively suppressed to slow the progressive loss of tear-producing tissue.
- Cyclosporine (Restasis, Vevye), a calcineurin inhibitor that suppresses the T-cell-driven inflammation and can improve Schirmer scores over months of use
- Lifitegrast (Xiidra), an integrin antagonist that interrupts the T-cell adhesion pathway, often with a faster onset
- Short-term topical steroids (such as loteprednol) for acute flares or as a bridge while longer-acting drops build up
- Systemic hydroxychloroquine, prescribed by the rheumatologist for systemic disease
Layer 3. Tear conservation
Often the single most impactful step for aqueous-deficient patients. Punctal plugs sit in the tear-drainage openings to slow outflow and keep natural tears and medication on the eye longer.
A 2025 meta-analysis of 17 studies found significant gains in tear breakup time, Schirmer scores, and OSDI, with an 86% plug retention rate. AJMC, 2025
Plugs work best after active inflammation is controlled; placing them in a highly inflamed eye can trap inflammatory mediators on the surface, so anti-inflammatory therapy usually comes first.
Layer 4. Advanced lubrication and surface protection
- Scleral lenses, large gas-permeable lenses that vault the cornea and hold a fluid reservoir all day, for severe disease
- Moisture chamber eyewear, wrap-around frames that create a humid microenvironment, a simpler option when scleral lenses are not tolerated
- Amniotic membrane (Prokera), a cryopreserved membrane worn briefly to deliver anti-inflammatory and regenerative signals to a damaged surface
Layer 5. In-office procedures
Used as adjuncts to the medical plan.
- Ocular surface irrigation (Rinsada), a single-use device that flushes inflammatory mediators and MMP-9 that drops cannot reach; ASCRS 2023 data reported a meaningful MMP-9 reduction per session
- Low-level light therapy, periocular photobiomodulation; a 2022 randomized trial in Nature Scientific Reports showed improved staining, Schirmer, and meibography (Nature, 2022)
- IPL (OptiLight) when a mixed, evaporative component coexists, which is common over time
- Lid debridement (BlephEx) and Demodex treatment (Xdemvy) when blepharitis or Demodex is also present
Layer 6. Systemic disease management
An essential partner to eye care. Do not manage Sjogren's as an eye condition alone; these are handled with rheumatology.
- Hydroxychloroquine (Plaquenil), a first-line DMARD that may improve fatigue and systemic activity
- Pilocarpine or cevimeline, muscarinic agonists that stimulate residual secretion, mainly for dry mouth but sometimes helpful for tears
- Rituximab, belimumab, and investigational biologics for more severe or refractory disease
- NSAIDs and corticosteroids for systemic inflammatory flares
Coordinated care, eye doctor and rheumatologist
Sjogren's dry eye should never be managed in isolation. The most effective model is ongoing communication between your eye care provider and your rheumatologist.
- Your eye doctor monitors the ocular surface, tracking staining, osmolarity, MMP-9, Schirmer, and corneal integrity at every visit
- Your rheumatologist tracks systemic disease activity, manages DMARDs, and screens for complications
- A worsening ocular surface can signal a systemic flare, and the rheumatologist should be notified
- When systemic treatment changes, the eye doctor should re-evaluate the surface, since some systemic agents affect the eyes
Find a dry eye doctor who understands Sjogren's
Our doctor locator shows practices equipped for the objective testing, osmolarity, MMP-9, Schirmer's, and staining, that Sjogren's care depends on.
Build a layered plan with your eye doctor
Find a practice equipped for the full Sjogren's dry eye workup and treatment, and shop preservative-free relief while you get set up.
